Journal article · 2022 · Open access

A targetable pathway in neutrophils mitigates both arterial and venous thrombosis

Lalitha V. Nayak, David R. Sweet, Asha Thomas, Stephanie D. Lapping, Kenneth A Kalikasingh, Annmarie Madera, Vinesh Vinayachandran, Roshan Padmanabhan, Neelakantan T. Vasudevan, Jay Myers, Alex Yee-Chen Huang, Alvin H. Schmaier and 4 more

Science Translational Medicine, 14(660), eabj7465 · Published 31 August 2022 · DOI 10.1126/scitranslmed.abj7465

Open PDFView at the publisherCite this paper

In brief

“A targetable pathway in neutrophils mitigates both arterial and venous thrombosis” is a 2022 journal article by Lalitha V. Nayak and 15 co-authors, published in Science Translational Medicine. OpenAlex counts 61 citations as of 19 November 2026, which puts it in the top 7% of works published in 2022 by citations. It is open access: the full text is free to read at PubMed Central.

Citations
61
Most cited in
2023 (15)
Field-weighted impact
6.74
References
44
Authors
16

Abstract

Arterial and venous thrombosis constitutes a major source of morbidity and mortality worldwide. Long considered as distinct entities, accumulating evidence indicates that arterial and venous thrombosis can occur in the same populations, suggesting that common mechanisms are likely operative. Although hyperactivation of the immune system is a common forerunner to the genesis of thrombotic events in both vascular systems, the key molecular control points remain poorly understood. Consequently, antithrombotic therapies targeting the immune system for therapeutics gain are lacking. Here, we show that neutrophils are key effectors of both arterial and venous thrombosis and can be targeted through immunoregulatory nanoparticles. Using antiphospholipid antibody syndrome (APS) as a model for arterial and venous thrombosis, we identified the transcription factor Krüppel-like factor 2 (KLF2) as a key regulator of neutrophil activation. Upon activation through genetic loss of KLF2 or administration of antiphospholipid antibodies, neutrophils clustered P-selectin glycoprotein ligand 1 (PSGL-1) by cortical actin remodeling, thereby increasing adhesion potential at sites of thrombosis. Targeting clustered PSGL-1 using nanoparticles attenuated neutrophil-mediated thrombosis in APS and KLF2 knockout models, illustrating the importance and feasibility of targeting activated neutrophils to prevent pathological thrombosis. Together, our results demonstrate a role for activated neutrophils in both arterial and venous thrombosis and identify key molecular events that serve as potential targets for therapeutics against diverse causes of immunothrombosis.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Nayak, L. V., Sweet, D. R., Thomas, A., Lapping, S. D., Kalikasingh, K. A., Madera, A., Vinayachandran, V., Padmanabhan, R., Vasudevan, N. T., Myers, J., Huang, A. Y.-C., Schmaier, A. H., Mackman, N., Liao, X., Maiseyeu, A., & Jain, M. K. (2022). A targetable pathway in neutrophils mitigates both arterial and venous thrombosis. Science Translational Medicine, 14(660), eabj7465. https://doi.org/10.1126/scitranslmed.abj7465

MLA 9

Nayak, Lalitha V., et al. “A targetable pathway in neutrophils mitigates both arterial and venous thrombosis.” Science Translational Medicine, vol. 14, no. 660, 2022, p. eabj7465. https://doi.org/10.1126/scitranslmed.abj7465.

Chicago

Nayak, Lalitha V., David R. Sweet, Asha Thomas, Stephanie D. Lapping, Kenneth A Kalikasingh, Annmarie Madera, Vinesh Vinayachandran, et al. 2022. “A targetable pathway in neutrophils mitigates both arterial and venous thrombosis.” Science Translational Medicine 14 (660): eabj7465. https://doi.org/10.1126/scitranslmed.abj7465.

Harvard

Nayak, L. V. et al. (2022) ‘A targetable pathway in neutrophils mitigates both arterial and venous thrombosis’, Science Translational Medicine, 14(660), p. eabj7465. doi:10.1126/scitranslmed.abj7465.

IEEE

L. V. Nayak et al., “A targetable pathway in neutrophils mitigates both arterial and venous thrombosis,” Science Translational Medicine, vol. 14, no. 660, p. eabj7465, 2022, doi: 10.1126/scitranslmed.abj7465.

BibTeX

@article{nayak2022targetable,
  title     = {{A targetable pathway in neutrophils mitigates both arterial and venous thrombosis}},
  author    = {Nayak, Lalitha V. and Sweet, David R. and Thomas, Asha and Lapping, Stephanie D. and Kalikasingh, Kenneth A and Madera, Annmarie and Vinayachandran, Vinesh and Padmanabhan, Roshan and Vasudevan, Neelakantan T. and Myers, Jay and Huang, Alex Yee-Chen and Schmaier, Alvin H. and Mackman, Nigel and Liao, Xudong and Maiseyeu, Andrei and Jain, Mukesh K.},
  journal   = {Science Translational Medicine},
  year      = {2022},
  volume    = {14},
  number    = {660},
  pages     = {eabj7465},
  doi       = {10.1126/scitranslmed.abj7465},
  url       = {https://doi.org/10.1126/scitranslmed.abj7465}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
202222
20231515
20241515
20251515
20261414

Its field-weighted citation impact is 6.74: it has been cited 6.74 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research

  • arterial thrombosis
  • venous thrombosis
  • neutrophils
  • KLF2
  • antiphospholipid syndrome
  • PSGL-1
  • P-selectin
  • neutrophil activation

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Nayak, L. V., Sweet, D. R., Thomas, A., Lapping, S. D., Kalikasingh, K. A., Madera, A., Vinayachandran, V., Padmanabhan, R., Vasudevan, N. T., Myers, J., Huang, A. Y.-C., Schmaier, A. H., Mackman, N., Liao, X., Maiseyeu, A., & Jain, M. K. (2022). A targetable pathway in neutrophils mitigates both arterial and venous thrombosis. Science Translational Medicine, 14(660), eabj7465. https://doi.org/10.1126/scitranslmed.abj7465

How many times has this paper been cited?

61 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at PubMed Central: sign in and open the PDF from this page.

Who wrote this paper?

Lalitha V. Nayak, David R. Sweet, Asha Thomas, Stephanie D. Lapping, Kenneth A Kalikasingh, Annmarie Madera, Vinesh Vinayachandran, Roshan Padmanabhan, Neelakantan T. Vasudevan, Jay Myers, Alex Yee-Chen Huang, Alvin H. Schmaier and 4 more.

What is the DOI of this paper?

10.1126/scitranslmed.abj7465, permanently at https://doi.org/10.1126/scitranslmed.abj7465. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.